AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript February 4, 2026 AbbVie Inc. beats earnings expectations. Reported ...

Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie ...

While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended ...

On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” ...

Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...

Over the next year and a half, hospitals’ supply chain teams should expect to see pharmacy price inflation temper while other ...

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales ...

By diving deeper into the dynamics of high-cost claims, employers can uncover valuable insights that pave the way for smart, ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Elevating CMS oversight operationalizes Any Willing Provider by mandating “reasonable and relevant” participation terms, ...

With so much volatility in the market, it’s a good time for investors to consider stocks that they can hold for the long haul. These compounders don’t have to make up a large part of your portfolio, ...

The S&P 500 touched 7,000 as tech stocks rallied on AI optimism, with investors focused on earnings, profitability and ...